Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and dyslipidemia
Not Applicable
- Conditions
- Hypercholesterolemia
- Registration Number
- JPRN-UMIN000018599
- Lead Sponsor
- Okayama University Hospital, Depertment of Cardiovascular Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)TG>400mg/dl 2)use of insulin 3)pregnant 4)allergy agignst treatment drug 5)severe liver disease 6)severe kideny disease 7)history of myocardial infarction or unstable angina within 3 months 8)secondary hyperlimidemia, drug-induced hyperlimidemia, familial hypercholeaterolemia 9)use of ezetimib or fibrate 10)subject who is not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in PCSK9 concentration after ezetimibe treatment
- Secondary Outcome Measures
Name Time Method